围术期非甾体抗炎药处方与全膝关节置换术后持续阿片类药物处方的关联:一项回顾性索赔数据库队列研究
该回顾性索赔数据库队列研究纳入789,736例既往未使用阿片类药物的初次全膝关节置换术成人患者,评估围术期处方非甾体抗炎药(NSAIDs)与术后90-180天持续阿片类药物处方索赔的关联。多因素logistic回归显示,围术期30天内NSAID处方与术后90天持续阿片类药物索赔的调整比值比为1.32(95%CI 1.30-1.35,p<0.001),180天为1.12(95%CI 1.10-1.15,p<0.001)。对乙酰氨基酚等其他镇痛药的类似分析未发现此种关联。
要点
- 围术期NSAID处方与全膝关节置换术后90天持续阿片类药物处方独立相关(aOR 1.32)。
- 该关联在180天时仍存在但效应减弱(aOR 1.12)。
- 对乙酰氨基酚等其他镇痛药未显示类似关联,提示NSAID特异性信号。
核心结论
- 围术期处方NSAID可能与全膝关节置换术后90天和180天持续阿片类药物处方索赔相关,即使在调整其他观察到的协变量后仍存在。
研究设计与样本
- 回顾性索赔数据库队列研究,使用美国健康索赔数据库识别2010年1月至2021年10月期间初次全膝关节置换术的既往未使用阿片类药物的成人患者,共789,736例。
- 采用多因素logistic回归模型评估围术期NSAID处方索赔与术后90天阿片类药物索赔的关联强度,并调整已知潜在混杂因素。
主要发现
- 在789,736例患者队列中,围术期30天内NSAID处方与术后90天持续阿片类药物索赔的调整比值比为1.32(95%CI 1.30-1.35),p<0.001。
- 围术期30天内NSAID处方与术后180天持续阿片类药物索赔的调整比值比为1.12(95%CI 1.10-1.15),p<0.001。
- 在考虑已知潜在混杂因素(包括既往膝痛和急性术后疼痛严重程度)后,90天时的效应估计仍然稳健。
- 对其他镇痛药(如对乙酰氨基酚)的类似分析未检测到此种关联。
临床怎么用
- 临床决策中应权衡围术期NSAID处方的风险与获益,并与患者讨论术后持续阿片类药物使用的潜在风险。
- 对既往未使用阿片类药物的全膝关节置换术患者,围术期NSAID处方后需关注术后90-180天阿片类药物持续使用的可能性。
局限性
- 本研究为回顾性索赔数据库分析,可能存在未测量的混杂因素。
- 索赔数据可能无法完全反映实际用药情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the mainstays of multimodal pain management. While effective for acute pain control, recent pre-clinical evidence has raised concerns regarding an association between NSAIDs and chronic pain and potential opioid use. Our objective was to explore the association between peri-operative use of prescription NSAIDs and the need for continued opioid prescriptions lasting 90-180 days in previously opioid-naïve patients undergoing total knee arthroplasty. A database of health claims in the USA was used to identify all opioid-naïve adult patients who underwent primary knee arthroplasty between January 2010 and October 2021. We evaluated the magnitude of association between peri-operative prescription NSAID claims and claims for opioids at 90 days postoperatively using multivariable logistic regression models. Secondary outcomes included: the magnitude of association between peri-operative NSAID prescription and claims for opioids at 180 days postoperatively; and identifying other potential factors associated with opioid claims at 90 days postoperatively. After risk adjustment using multivariable logistic regression models in the 789,736-patient cohort, the adjusted odds ratio (95%CI) for a continuous claim of opioids at 90 and 180 days postoperatively among patients with a peri-operative NSAID prescription within 30 days was 1.32 (1.30-1.35), p < 0.001; and 1.12 (1.10-1.15), p < 0.001, respectively. This estimate of effect remained robust at 90 days after accounting for known potential confounders, including pre-existing knee pain and acute postoperative pain severity. Similar analysis of other pain medications (e.g. paracetamol) did not detect such an association. This population-based cohort study suggests that peri-operative prescription NSAID use may be associated with continued opioid prescription claims at 90 and 180 days after knee arthroplasty, even after adjusting for other observed covariates for continuous opioid claims. These novel findings can inform clinical decision-making for post-surgical pain management, risk-benefit discussions with patients and future research.
引用
- Hussain N, Brull R, Gilron I, et al. Association of peri-operative prescription of non-steroidal anti-inflammatory drugs with continued prescription of opioids after total knee arthroplasty: a retrospective claims-based cohort study. Anaesthesia. 2024. PMID: 38385772. doi:10.1111/anae.16259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。